Advanced Search

Home > Journals > Minerva Chirurgica > Past Issues > Minerva Chirurgica 2014 February;69(1) > Minerva Chirurgica 2014 February;69(1):27-35



A Journal on Surgery

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,877

Frequency: Bi-Monthly

ISSN 0026-4733

Online ISSN 1827-1626


Minerva Chirurgica 2014 February;69(1):27-35


Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC)

Robella M. 1, Vaira M. 1, Marsanic P. 1, Mellano A. 1, Borsano A. 1, Cinquegrana A. 1, Sottile A. 2, De Simone M. 1

1 Unit of Surgical Oncology, IRCCS (Scientific Institute for Cancer Research and Treatment), Candiolo, Turin, Italy;
2 Laboratory Medicine, IRCCS (Scientific Institute for Cancer Research and Treatment), Candiolo, Turin, Italy

AIM: Ovarian cancer may be considered as an “intraperitoneal disease” by itself. When surgical removal associated with systemic chemotherapy fails, usually, the history of the patients is characterized by poor prognosis. Some encouraging results have been reported by the treatment of peritoneal carcinomatosis (PC) from ovarian cancer by complete surgical cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). The purpose of this article was to evaluate the survival benefit and the morbidity of patients with ovarian cancer treated at our institution by cytoreductive surgery associated with hyperthermic intraperitoneal perioperative chemotherapy (HIPEC).
METHODS: Between October 1995 and December 2012 more than 600 operations for PC were performed; in 308 cases surgical cytoreduction associated with HIPEC was carried out. Eighty-five patients treated by cytoreduction associated with HIPEC were affected by recurrent epithelial ovarian cancer (EOC). Statistical analysis was performed on 70 patients (last 15 patients were too recent for evaluation). Two trials were applied: 1) patients presenting first peritoneal relapse after surgery and systemic chemotherapy (CT), 6 months later from last CT administration; 2) multiple relapse patients.
RESULTS: On 70 patients, morbidity and mortality rates were 35.7% and 7.1%, respectively. Overall median survival was 42.0 months, but in primary EOC was 48.0 months and in recurrent EOC was 28 months (P=0.12). Statistical analysis revealed that the completeness of cytoreduction was the most statistically significant factor related to survival: in completely citoreduced patients, overall survival was 48 months.
CONCLUSION: Citoreductive surgery associated to platinum compounds HIPEC is feasible and relatively safe in recurrent and primary PC from ovarian cancer. Better selection of patients and second-look surgery in high risk-patients have to be investigated to improve those encouraging results.

language: English


top of page